NYSE:EBS (USA) Also trade in: Germany UK

Emergent BioSolutions Inc

$ 44.15 0.22 (0.5%)
Volume: 303,709 Avg Vol (1m): 440,659
Market Cap $: 2.27 Bil Enterprise Value $: 2.87 Bil
P/E (TTM): 54.46 P/B: 2.31
Earnings Power Value -4.51
Net Current Asset Value -12.46
Tangible Book -1.53
Projected FCF 27.37
Median P/S Value 42.34
Graham Number 0
Peter Lynch Value 8.99
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 5.2/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 0.19
Cash-To-Debt range over the past 10 years
Min: 0.14, Med: 1.79, Max: 10000
Current: 0.19
0.14
10000
Equity-to-Asset 0.46
Equity-to-Asset range over the past 10 years
Min: 0.33, Med: 0.68, Max: 0.85
Current: 0.46
0.33
0.85
Debt-to-Equity 0.75
Debt-to-Equity range over the past 10 years
Min: 0.01, Med: 0.27, Max: 0.79
Current: 0.75
0.01
0.79
Debt-to-EBITDA 4.99
Debt-to-EBITDA range over the past 10 years
Min: 0.08, Med: 1.43, Max: 5.17
Current: 4.99
0.08
5.17
Interest Coverage 3.74
Interest Coverage range over the past 10 years
Min: 3.74, Med: 18.83, Max: 6594.5
Current: 3.74
3.74
6594.5
Piotroski F-Score 4
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 2.16
DISTRESS
GREY
SAFE
Beneish M-Score -3.12
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 5.21%
WACC 10.65%

Profitability & Growth : 7/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % 8.43
Operating Margin range over the past 10 years
Min: 8.43, Med: 19.34, Max: 28.92
Current: 8.43
8.43
28.92
Net Margin % 4.87
Net Margin range over the past 10 years
Min: 4.87, Med: 10.28, Max: 18.07
Current: 4.87
4.87
18.07
ROE % 4.35
ROE range over the past 10 years
Min: 4.35, Med: 7.65, Max: 16.93
Current: 4.35
4.35
16.93
ROA % 2.68
ROA range over the past 10 years
Min: 2.68, Med: 5.2, Max: 12.24
Current: 2.68
2.68
12.24
ROC (Joel Greenblatt) % 11.01
ROC (Joel Greenblatt) range over the past 10 years
Min: 11.01, Med: 22.33, Max: 43.92
Current: 11.01
11.01
43.92
3-Year Total Revenue Growth Rate 16.90
3-Year Revenue Growth Rate range over the past 10 years
Min: -1.1, Med: 8.8, Max: 31.3
Current: 13.7
-1.1
31.3
3-Year Total EBITDA Growth Rate -4.70
3-Year EBITDA Growth Rate range over the past 10 years
Min: -33.4, Med: -2.1, Max: 46.8
Current: -7.4
-33.4
46.8
3-Year EPS w/o NRI Growth Rate -15.50
N/A

» EBS's 30-Y Financials

Financials (Next Earnings Date: 2019-08-02)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NYSE:EBS

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325412    SIC : 2834
Compare NAS:HALO XSWX:GALE OCSE:ALK B NAS:ARWR HKSE:00570 SZSE:300009 NAS:CRSP NAS:ICPT XKRX:084990 NAS:PTCT SHSE:600201 NAS:MYOK NAS:IMMU NAS:XNCR TSE:4974 NAS:INSM NYSE:BHVN XBRU:TUB NAS:LGND SZSE:002653
Traded in other countries ER4.Germany 0IGA.UK
Address 400 Professional Drive, Suite 400, Gaithersburg, MD, USA, 20879
Emergent BioSolutions Inc is a global biotechnology company that offers biopharmaceutical products to healthcare providers and governments. The company has two operating divisions: biodefense and biosciences. Its specialty biodefense division focuses on countermeasures that address public health threats. The U.S. government is the primary purchaser of these products and often provides substantial funding for their development. Emergent's biosciences business is primarily focused on hematology and oncology therapeutics, with a secondary focus on transplantation, infectious disease, and autoimmunity.

Ratios

Current vs industry vs history
PE Ratio (TTM) 54.46
PE Ratio range over the past 10 years
Min: 7.53, Med: 24.84, Max: 73.47
Current: 54.46
7.53
73.47
Forward PE Ratio 14.86
N/A
PE Ratio without NRI 54.46
PE without NRI range over the past 10 years
Min: 7.53, Med: 23.96, Max: 73.47
Current: 54.46
7.53
73.47
Price-to-Owner-Earnings 36.39
Price-to-Owner-Earnings range over the past 10 years
Min: 5.9, Med: 33.97, Max: 1470
Current: 36.39
5.9
1470
PB Ratio 2.31
PB Ratio range over the past 10 years
Min: 1.03, Med: 1.95, Max: 3.78
Current: 2.31
1.03
3.78
PS Ratio 2.68
PS Ratio range over the past 10 years
Min: 1.49, Med: 2.55, Max: 5.26
Current: 2.68
1.49
5.26
Price-to-Free-Cash-Flow 33.30
Price-to-Free-Cash-Flow range over the past 10 years
Min: 5.21, Med: 25.33, Max: 706.67
Current: 33.3
5.21
706.67
Price-to-Operating-Cash-Flow 15.12
Price-to-Operating-Cash-Flow range over the past 10 years
Min: 3.88, Med: 14.54, Max: 97.72
Current: 15.12
3.88
97.72
EV-to-EBIT 39.69
EV-to-EBIT range over the past 10 years
Min: 4.3, Med: 14.5, Max: 50.5
Current: 39.69
4.3
50.5
EV-to-EBITDA 19.27
EV-to-EBITDA range over the past 10 years
Min: 4.1, Med: 10.7, Max: 26.9
Current: 19.27
4.1
26.9
EV-to-Revenue 3.38
EV-to-Revenue range over the past 10 years
Min: 1.1, Med: 2.5, Max: 5.3
Current: 3.38
1.1
5.3
PEG Ratio 6.14
PEG Ratio range over the past 10 years
Min: 0.47, Med: 1.8, Max: 190.48
Current: 6.14
0.47
190.48
Shiller PE Ratio 41.89
Shiller PE Ratio range over the past 10 years
Min: 15.28, Med: 33, Max: 63.34
Current: 41.89
15.28
63.34
Current Ratio 2.13
Current Ratio range over the past 10 years
Min: 1.22, Med: 4.25, Max: 7.37
Current: 2.13
1.22
7.37
Quick Ratio 1.28
Quick Ratio range over the past 10 years
Min: 0.76, Med: 3.63, Max: 6.46
Current: 1.28
0.76
6.46
Days Inventory 171.63
Days Inventory range over the past 10 years
Min: 87.55, Med: 134.7, Max: 214.89
Current: 171.63
87.55
214.89
Days Sales Outstanding 38.24
Days Sales Outstanding range over the past 10 years
Min: 36.05, Med: 85.13, Max: 124.36
Current: 38.24
36.05
124.36
Days Payable 80.57
Days Payable range over the past 10 years
Min: 80.57, Med: 140.95, Max: 350.8
Current: 80.57
80.57
350.8

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -9.30
3-Year Share Buyback Rate range over the past 10 years
Min: -13.3, Med: -5.2, Max: -1.5
Current: -9.3
-13.3
-1.5

Valuation & Return

Current vs industry vs history
Price-to-Projected-FCF 1.61
Price-to-Intrinsic-Value-Projected-FCF range over the past 10 years
Min: 1.06, Med: 1.99, Max: 3.38
Current: 1.61
1.06
3.38
Price-to-Median-PS-Value 1.04
Price-to-Median-PS-Value range over the past 10 years
Min: 0.31, Med: 0.94, Max: 1.87
Current: 1.04
0.31
1.87
Price-to-Peter-Lynch-Fair-Value 4.91
Price-to-Peter-Lynch-Fair-Value range over the past 10 years
Min: 0.57, Med: 1.23, Max: 7.19
Current: 4.91
0.57
7.19
Earnings Yield (Joel Greenblatt) % 2.45
Earnings Yield (Greenblatt) range over the past 10 years
Min: 2, Med: 6.9, Max: 23.2
Current: 2.45
2
23.2
Forward Rate of Return (Yacktman) % 13.04
Forward Rate of Return range over the past 10 years
Min: -11.8, Med: 5.65, Max: 22.2
Current: 13.04
-11.8
22.2

More Statistics

Revenue (TTM) (Mil) $ 855.19
EPS (TTM) $ 0.81
Beta 1.75
Volatility % 49.69
52-Week Range $ 39.64 - 73.89
Shares Outstanding (Mil) 51.2

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 4
Positive ROA Y
Positive CFROA Y
Higher ROA yoy N
CFROA > ROA Y
Lower Leverage yoy N
Higher Current Ratio yoy N
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy Y